文献速递前列腺癌

黑人白人前列腺癌患者ADT后心血管事件与死亡风险的真实世界分析

Real-world analyses of major adverse cardiovascular events and mortality risk after androgen deprivation therapy initiation in black vs. white prostate cancer patients.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2025-04-18

基于DRG真实世界数据库,纳入1991—2020年接受至少一次ADT的前列腺癌患者,用多变量回归比较黑人与白人患者的主要不良心血管事件(MACE)和全因死亡风险。结果显示白人患者MACE风险更高(1年4.0% vs 2.4%,4年21.0% vs 13.3%),死亡率亦更高(1年2.6% vs 1.6%,4年18.1% vs 11.7%)。作者认为黑人种族与较低MACE率和更好生存相关,原因尚不明确。

要点

  • ADT启动后白人患者MACE风险高于黑人(4年21.0% vs 13.3%)
  • 白人患者全因死亡风险亦高于黑人(4年18.1% vs 11.7%)
  • 该真实世界研究不限于去势抵抗性前列腺癌患者

核心结论

  • 在白人前列腺癌患者中,ADT启动后MACE和全因死亡发生率均高于黑人患者。
  • 黑人种族与接受ADT治疗男性较低的MACE率和更好的生存相关。
  • 选择偏倚、潜在生物学或其他因素是否导致这些差异仍未知。

研究设计与样本

  • 历史性、纵向患者层面数据来自Decision Resources Group(现Clarivate)真实世界证据库。
  • 分析纳入1991—2020年接受至少一次ADT的前列腺癌患者。
  • 采用多变量回归模型校正基线转移、BMI(<18.5 vs ≥18.5 kg/m2)、肿瘤科vs泌尿科设置、拮抗剂vs激动剂、个人MACE史、吸烟史、基线PSA(>4 vs ≤4 ng/mL)、种族(白人vs黑人)、他汀使用、年龄每增加1岁、族裔(非西班牙裔vs西班牙裔)、ADT暴露每增加1年、糖尿病、高血压和家族MACE史。

主要发现

  • ADT启动后1年MACE风险白人4.0%、黑人2.4%;4年白人21.0%、黑人13.3%。
  • ADT启动后1年死亡率黑人1.6%、白人2.6%;4年黑人11.7%、白人18.1%。

临床怎么用

  • 临床中应关注白人前列腺癌患者ADT启动后的MACE和死亡风险,可能需加强心血管风险监测。
  • 黑人患者ADT后MACE和死亡风险较低,但原因未明,不应据此改变ADT决策。

局限性

  • 原文未明确报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prostate cancer(PCa) patients treated with androgen deprivation therapy(ADT) may experience major adverse cardiovascular events(MACE) [1]. Racial disparities in PCa incidence and outcomes have been noted. In contrast to older studies, three recent studies found significantly longer overall survival in Black vs. White patients: 2019 meta-analysis of nine phase III trials in men with metastatic castration-resistant PCa(CRPC) (n = 8820) [2]; 2020 registry study in men with metastatic CRPC (n = 1902) [3]; and 2023 study in men with non-metastatic CRPC (n = 12,992) [4]. Our "real-world" data study compared MACE and all-cause mortality risk for Black vs. White PCa patients. Compared to prior studies [1-4], our study encompassed a broader scope and was not exclusive to CRPC patients. METHODS: Historical, longitudinal patient-level were collected from the Decision Resources Group (DRG, now Clarivate) Real World Evidence repository. The analysis included PCa patients receiving ≥1 ADT 1991-2020. Multivariable regression model accounted for baseline metastasis, BMI (<18.5 vs. ≥18.5 kg/m2), oncology vs. urology setting, antagonist vs. agonist, personal MACE history, tobacco history, baseline prostate-specific antigen (>4 vs. ≤4 ng/mL), race (White vs. Black), statin use, increasing age per year, ethnicity (non-Hispanic vs. Hispanic), increasing ADT exposure per year, diabetes, hypertension, and family MACE history. RESULTS: MACE risk was higher for White patients than Black (4.0% vs. 2.4% at one year after ADT initiation; 21.0% vs. 13.3% at four years). Mortality risk after ADT initiation was 1.6% and 2.6% at 1 year and 11.7% and 18.1% at 4 years for Black and White patients, respectively. CONCLUSIONS: Our analysis reveals a unique finding that MACE and all-cause mortality incidence were higher in White vs. Black patients. Black race is associated with lower MACE rates and improved survival for men undergoing ADT treatment. Whether selection bias, underlying biology or other factors are responsible for these differences remains unknown.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Moul JW, Boldt-Houle DM, Roach M, et al. Real-world analyses of major adverse cardiovascular events and mortality risk after androgen deprivation therapy initiation in black vs. white prostate cancer patients. Prostate Cancer Prostatic Dis. 2025. PMID: 40251347. doi:10.1038/s41391-025-00963-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。